Quick Listen: Scrip's Five Must-Know Things

In this week's episode of Five Must-Know Things: Leqembi’s US treatment infrastructure; Novartis backs out of BeiGene deal; Transgene’s new CEO’s plans; Japanese firms’ R&D success; and a look at deal-making in the first half.

Scrip Five Must Know Things
weekly audio roundup of selected content from Scrip's global team

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 14 July 2023, including: Leqembi’s US treatment infrastructure; Novartis AG backs out of BeiGene, Ltd. deal; Transgene S.A.’s...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip